$14.21
At close: Apr 28 EDT
$14.06
-0.15-1.06%
Pre-Market: 5:30 AM EDT
Comments
Loading...
Keros Therapeutics Analyst Ratings and Price Targets | NASDAQ:KROS | Benzinga
Keros Therapeutics Inc has a consensus price target of $30.67 based on the ratings of 15 analysts. The high is $76 issued by B of A Securities on September 12, 2024. The low is $15 issued by Wedbush on April 1, 2025. The 3 most-recent analyst ratings were released by Truist Securities, Wedbush, and HC Wainwright & Co. on April 9, 2025, April 1, 2025, and April 1, 2025, respectively. With an average price target of $26.67 between Truist Securities, Wedbush, and HC Wainwright & Co., there's an implied 89.66% upside for Keros Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Wedbush
HC Wainwright & Co.
Wells Fargo
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Keros Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/09/2025 | Buy Now | 77.81% | Truist Securities | Srikripa Devarakonda44% | $43 → $25 | Maintains | Buy | Get Alert |
| 04/01/2025 | Buy Now | 6.69% | Wedbush | Yun Zhong36% | $15 → $15 | Reiterates | Neutral → Neutral | Get Alert |
| 04/01/2025 | Buy Now | 184.5% | HC Wainwright & Co. | Andrew Fein56% | $40 → $40 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 84.92% | Wells Fargo | Tiago Fauth43% | $28 → $26 | Maintains | Overweight | Get Alert |
| 02/27/2025 | Buy Now | 184.5% | HC Wainwright & Co. | Andrew Fein56% | $47 → $40 | Maintains | Buy | Get Alert |
| 01/21/2025 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal37% | — | Downgrade | Overweight → Neutral | Get Alert |
| 01/17/2025 | Buy Now | 6.69% | Piper Sandler | Joseph Catanzaro43% | $40 → $15 | Maintains | Overweight | Get Alert |
| 01/17/2025 | Buy Now | 6.69% | Wedbush | Andreas Argyrides69% | $47 → $15 | Downgrade | Outperform → Neutral | Get Alert |
| 01/17/2025 | Buy Now | — | Guggenheim | Vamil Divan75% | — | Reiterates | Neutral → Neutral | Get Alert |
| 01/16/2025 | Buy Now | 191.61% | Scotiabank | Greg Harrison43% | $44 → $41 | Maintains | Sector Outperform | Get Alert |
| 01/16/2025 | Buy Now | 63.58% | Oppenheimer | Andreas Argyrides69% | $63 → $23 | Maintains | Outperform | Get Alert |
| 12/23/2024 | Buy Now | 205.83% | Truist Securities | Srikripa Devarakonda44% | $100 → $43 | Maintains | Buy | Get Alert |
| 12/16/2024 | Buy Now | 348.08% | Oppenheimer | Andreas Argyrides69% | $102 → $63 | Maintains | Outperform | Get Alert |
| 12/16/2024 | Buy Now | — | Guggenheim | Vamil Divan75% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/13/2024 | Buy Now | 99.15% | Wells Fargo | Tiago Fauth43% | $11 → $28 | Maintains | Overweight | Get Alert |
| 12/13/2024 | Buy Now | 212.94% | Scotiabank | Greg Harrison43% | $77 → $44 | Maintains | Sector Outperform | Get Alert |
| 12/13/2024 | Buy Now | 234.28% | HC Wainwright & Co. | Andrew Fein56% | $100 → $47 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | — | William Blair | Matt Phipps28% | — | Downgrade | Outperform → Market Perform | Get Alert |
| 12/12/2024 | Buy Now | — | TD Cowen | Tyler Van Buren44% | — | Downgrade | Buy → Hold | Get Alert |
| 12/12/2024 | Buy Now | — | BTIG | Julian Harrison40% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/11/2024 | Buy Now | 689.47% | Wells Fargo | Tiago Fauth43% | $88 → $111 | Maintains | Overweight | Get Alert |
| 12/05/2024 | Buy Now | 625.46% | Guggenheim | Vamil Divan75% | $96 → $102 | Maintains | Buy | Get Alert |
| 12/04/2024 | Buy Now | — | Guggenheim | Vamil Divan75% | — | Reiterates | Buy → Buy | Get Alert |
| 11/22/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal37% | — | Reiterates | → Overweight | Get Alert |
| 11/07/2024 | Buy Now | 611.24% | HC Wainwright & Co. | Andrew Fein56% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 10/24/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal37% | — | Reiterates | → Overweight | Get Alert |
| 10/16/2024 | Buy Now | 447.65% | Scotiabank | Greg Harrison43% | → $77 | Initiates | → Sector Outperform | Get Alert |
| 09/23/2024 | Buy Now | 582.79% | Guggenheim | Vamil Divan75% | → $96 | Initiates | → Buy | Get Alert |
| 09/12/2024 | Buy Now | 440.54% | B of A Securities | Greg Harrison43% | $81 → $76 | Maintains | Buy | Get Alert |
| 06/25/2024 | Buy Now | 625.46% | Oppenheimer | Andreas Argyrides69% | → $102 | Initiates | → Outperform | Get Alert |
| 06/18/2024 | Buy Now | 611.24% | Truist Securities | Srikripa Devarakonda44% | $100 → $100 | Maintains | Buy | Get Alert |
| 06/18/2024 | Buy Now | 611.24% | HC Wainwright & Co. | Andrew Fein56% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 525.89% | Wells Fargo | Tiago Fauth43% | $77 → $88 | Maintains | Overweight | Get Alert |
| 05/09/2024 | Buy Now | 611.24% | HC Wainwright & Co. | Andrew Fein56% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 646.8% | Piper Sandler | Joseph Catanzaro43% | → $105 | Maintains | Overweight | Get Alert |
| 03/13/2024 | Buy Now | 611.24% | Truist Securities | Srikripa Devarakonda44% | → $100 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 611.24% | HC Wainwright & Co. | Andrew Fein56% | $100 → $100 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 447.65% | Wells Fargo | Tiago Fauth43% | $60 → $77 | Maintains | Overweight | Get Alert |
| 12/08/2023 | Buy Now | 326.74% | Wells Fargo | Tiago Fauth43% | → $60 | Initiates | → Overweight | Get Alert |
| 11/13/2023 | Buy Now | 511.66% | Wedbush | Andreas Argyrides69% | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 08/31/2023 | Buy Now | 511.66% | Wedbush | Andreas Argyrides69% | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | Buy Now | 611.24% | HC Wainwright & Co. | Andrew Fein56% | → $100 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 511.66% | Wedbush | Andreas Argyrides69% | → $86 | Reiterates | Outperform → Outperform | Get Alert |
| 08/07/2023 | Buy Now | 611.24% | HC Wainwright & Co. | Andrew Fein56% | → $100 | Reiterates | → Buy | Get Alert |
| 07/31/2023 | Buy Now | 511.66% | Wedbush | Andreas Argyrides69% | → $86 | Initiates | → Outperform | Get Alert |
| 07/26/2023 | Buy Now | 362.3% | B of A Securities | Greg Harrison43% | → $65 | Initiates | → Buy | Get Alert |
| 06/09/2023 | Buy Now | 611.24% | HC Wainwright & Co. | Andrew Fein56% | → $100 | Reiterates | → Buy | Get Alert |
| 05/08/2023 | Buy Now | 611.24% | HC Wainwright & Co. | Andrew Fein56% | → $100 | Reiterates | → Buy | Get Alert |
| 05/05/2023 | Buy Now | 682.36% | Piper Sandler | Joseph Catanzaro43% | $120 → $110 | Maintains | Overweight | Get Alert |
| 03/06/2023 | Buy Now | 611.24% | HC Wainwright & Co. | Andrew Fein56% | → $100 | Reiterates | → Buy | Get Alert |
| 02/14/2023 | Buy Now | — | Cowen & Co. | Tyler Van Buren44% | — | Initiates | → Outperform | Get Alert |
| 12/13/2022 | Buy Now | 646.8% | BTIG | Julian Harrison40% | $95 → $105 | Maintains | Buy | Get Alert |
| 10/18/2022 | Buy Now | 611.24% | Truist Securities | Srikripa Devarakonda44% | → $100 | Initiates | → Buy | Get Alert |
| 07/26/2022 | Buy Now | 468.99% | BTIG | Julian Harrison40% | → $80 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Keros Therapeutics (KROS) stock?
The latest price target for Keros Therapeutics (NASDAQ:KROS) was reported by Truist Securities on April 9, 2025. The analyst firm set a price target for $25.00 expecting KROS to rise to within 12 months (a possible 77.81% upside). 34 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Keros Therapeutics (KROS)?
The latest analyst rating for Keros Therapeutics (NASDAQ:KROS) was provided by Truist Securities, and Keros Therapeutics maintained their buy rating.
When was the last upgrade for Keros Therapeutics (KROS)?
There is no last upgrade for Keros Therapeutics
When was the last downgrade for Keros Therapeutics (KROS)?
The last downgrade for Keros Therapeutics Inc happened on January 21, 2025 when Cantor Fitzgerald changed their price target from N/A to N/A for Keros Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Keros Therapeutics (KROS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Keros Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Keros Therapeutics was filed on April 9, 2025 so you should expect the next rating to be made available sometime around April 9, 2026.
Is the Analyst Rating Keros Therapeutics (KROS) correct?
While ratings are subjective and will change, the latest Keros Therapeutics (KROS) rating was a maintained with a price target of $43.00 to $25.00. The current price Keros Therapeutics (KROS) is trading at is $14.06, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
